243 related articles for article (PubMed ID: 31005161)
1. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Assessment of
Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
[TBL] [Abstract][Full Text] [Related]
3. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
[TBL] [Abstract][Full Text] [Related]
5. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
7. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
8. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
Reuss DE; Mamatjan Y; Schrimpf D; Capper D; Hovestadt V; Kratz A; Sahm F; Koelsche C; Korshunov A; Olar A; Hartmann C; Reijneveld JC; Wesseling P; Unterberg A; Platten M; Wick W; Herold-Mende C; Aldape K; von Deimling A
Acta Neuropathol; 2015 Jun; 129(6):867-73. PubMed ID: 25962792
[TBL] [Abstract][Full Text] [Related]
9. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
[TBL] [Abstract][Full Text] [Related]
10. Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas.
Lasocki A; Buckland ME; Molinaro T; Xie J; Whittle JR; Wei H; Gaillard F
Neuroradiology; 2023 Aug; 65(8):1215-1223. PubMed ID: 37316586
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
12. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
[TBL] [Abstract][Full Text] [Related]
13. The role of apparent diffusion coefficient in the grading of adult isocitrate dehydrogenase-mutant astrocytomas: relationship with the Ki-67 proliferation index.
She Y; Liu X; Jiang J; Wang X; Niu Q; Zhou J
Acta Radiol; 2024 May; 65(5):489-498. PubMed ID: 38644751
[TBL] [Abstract][Full Text] [Related]
14. A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.
Tan Y; Zhang ST; Wei JW; Dong D; Wang XC; Yang GQ; Tian J; Zhang H
Eur Radiol; 2019 Jul; 29(7):3325-3337. PubMed ID: 30972543
[TBL] [Abstract][Full Text] [Related]
15. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
16. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
[TBL] [Abstract][Full Text] [Related]
17. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
[TBL] [Abstract][Full Text] [Related]
18. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
19. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
[TBL] [Abstract][Full Text] [Related]
20. Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas.
Setyawan NH; Choridah L; Nugroho HA; Malueka RG; Dwianingsih EK
Cancer Imaging; 2024 Jan; 24(1):3. PubMed ID: 38167551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
